Breaking down the barriers to drug development
9 Jan 2015
Dr. Francoise Meunier, EORTC Director General, Sir Michael Rawlins, former chair of NICE, and Robert Strieter, Novartis Institutes for Biomedical Research discuss translational medicine in respiratory disease in Prof. Peter Barnes’ latest instalment of ERS Vision. The film looks at ways to break down the barriers that obstruct and delay the development of new medicines at every stage of the discovery process.
Leading experts in the field tackle issues such as data protection, risk management, protocol development and European regulations, and emphasise the importance of developing active collaborations between the different stakeholders involved in the drug development process.
Related News
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
